Viking Therapeutics Option Alert: Jan 16 $75 Puts at the Ask: 200 vs 437 OI; Earnings 4/23 After Close [est] 

Viking Therapeutics Option Alert: Jan 16 $75 Puts at the Ask: 200 @ $49.3 vs 437 OI; Earnings 4/23 After Close [est] Ref=$26.1701

Viking Therapeutics

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

ACHR

ASTS

COST

NBIS

NVDA

PLTR

SMCI

VKTX

Stocks tried to stage a weak rally to close the week after the latest reading on inflation came in line with expectations. However, the longer-term direction for stocks may come down to whether investors look at the

MarketBeat Week in Review – 02/24 - 02/28

RHHBY


([content-module:CompanyOverview, NASDAQ:VKTX)
The GLP-1 industry is currently an oligopoly ruled by two pharmaceutical giants, Novo Nordisk A/S (NYSE:NVO), maker of semaglutide under the Ozempic and Wegovy name

Viking Therapeutics: Could GLP-1 Maker Be Acquired Pre-Approval?

Bangkok,,Thailand,-,January,14,,2024,:,Garmin,Epix,Pro

News

Markets

Movers

Trading Ideas

ANDE

APPN

ATGL

COMP

GRMN

Hims & Hers Health, Inc. Class A Common Stock

HIMS

IBRX

MCHP

SEDG

Garmin Posts Better-Than-Expected Results, Joins SolarEdge Technologies, Compass, Appian And Other Big Stocks Moving Higher On Wednesday

Viking Therapeutics Inc

Press Releases

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX

Small Cap

Viking Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity

Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2024 on February 5, 2025

Earnings

Viking Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals

Arcellx

Alvotech

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. - Common Stock

Arrowhead Pharma

Beam Therapeutics

Biohaven

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Denali Therapeutics

Amicus Therapeutics

Immunovant

Mirum Pharmaceuticals, Inc. - common stock

Mirum Pharmaceuticals

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

Metsera

NewAmsterdam Pharma Company N.V. - Ordinary Shares

NewAmsterdam Pharma Co

Protagonist Therapeutics, Inc. - Common Stock

Protagonist Therapeutics

Avidity Biosciences

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals

Rhythm Pharmaceuticals, Inc. - Common Stock

Rhythm Pharmaceuticals

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding

Twist Bioscience Corporation - Common Stock

Twist Bioscience

Vericel

Veracyte

Zai Lab Limited - American Depositary Shares

Comments

Viking Therapeutics

Unusual Options Activity for

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga